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Accurate imaging of the thymus is essential in the diagnosis and surgical treatment of both neoplastic and nonneoplastic conditions.
Imaging of the thymus is a rather complex task, which affects both initial diagnosis and further surgical treatment planning.
Imaging techniques include a wide armamentary of possibilities, from the most frequently used computed tomography (CT) to
18-fluorodeoxyglucose positron emission tomography- (18-FDG-PET-) CT and chemical shift magnetic resonance imaging (CS-
MRI). In cases where surgical treatment is involved diagnostic imaging is of pivotal importance, not only in distinguishing benign
frommalignant disease but also in making a way among subtypes of thymic conditions.The article presents a current review of the
advantages and backdrops of different imaging techniques used in the diagnosis of benign and malignant thymic conditions, with
emphasis on differential imaging of thymic hyperplasia (TH), ectopic thymic tissue (ETT), and thymic epithelial tumors (TETs),
with special attention to the importance of MR imaging according to the new TNM classification of thymic epithelial tumors.
1. Introduction
Accurate diagnostic imaging is of great importance in the
treatment management of thymic pathologies. Regarding
thymectomy, there are three important topics which are sig-
nificant during a discussion between a radiologist and a tho-
racic surgeon: (1) differentiating between thymic hyperplasia
(TH) and thymoma (THA), (2) deciding whether a possible
thymoma invades surrounding tissues, and (3) declaring the
presence of ectopic thymic tissue (ETT) around the thymus.
The answers given by the radiologist absolutely predict the
decision of the thoracic surgeon.The diagnosis of THA alone
is an absolute indication of thymectomy, though differing
thymic abnormalities such as TH without myasthenia gravis
(MG) should not be treated surgically. In cases of THA
or thymic carcinoma (TC) treatment planning is based on
imaging results. Thus dilemmas arise, whether it is possible
to carry out a primary resection or neoadjuvant treatment
should be the first step and how can the extent of resection
be defined? In cases of MG it is very important to evaluate
any lesion in themediastinumwhich could raise the suspicion
of ETT, because surgical removal of these lesions can highly
improve the success rate of a thymectomy. Our article deals
with the role of preoperative imaging and its effects on sur-
gical decision making in the most relevant conditions of the
thymus.
2. Thymic Hyperplasia or Thymoma
The rate of unnecessary or nontherapeutic thymectomies
carried out according to a previous CT diagnosis is 43.8% (of
which 17.1% are thymic hyperplasia cases) which emphasizes
the importance of accurate preoperative diagnosis of thymic
lesions [1]. This is an important question for a thoracic
surgeon because presence of THA means an absolute indi-
cation for surgery, while TH without MG is to be treated
nonsurgically. Preoperative imaging must have a definitive
answer to this dilemma which greatly influences surgical
decision making. Although chest CT is considered to be the
routinely used modality in the imaging of thymic lesions,
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in the differentiation between TH and THA, in cases where
preoperative diagnosis is ambiguous, MR imaging should be
performed [2, 3].
2.1. MRI. In recent years MRI has integrated two important
sequences into its armamentary, namely, fat suppression and
chemical shift imaging. Due to the presence of both fat
and water, thymic tissue around the tumor will show signal
intensity loss on opposed-phase imaging; hence chemical
shift imaging can be useful in pointing out the tumor margin
and rate of invasion. In older age thymic tissue has already
almost completely been replaced by fat; therefore in older
patients fat suppression imaging should be the method of
choice to define exact tumor margins. With the use of fat
suppression-MRI (FS-MRI) and chemical shift-MRI (CS-
MRI), diagnosis can be more accurate. CS-MRI is able to
differentiate TH from THA [2] and according to the study
of Li et al., differentiating between these two entities is much
more accurate using FS-MRI and CS-MRI. In case of young
patients CS-MRI proved to be better than CT, conventional
MRI, or fat suppression imaging in distinguishing TH from
THAand locating the exact tumormargin. In elderly patients,
fat suppression imaging is the right choice, especially in cases
of THA [3]. Priola et al. analyzed the qualitative and quanti-
tative values of CT and CS-MRI in differentiating between
THA and lymphoid thymic hyperplasia (lTH) among 83
patients with MG. In terms of qualitative values, the accurate
diagnosis was achieved in 86.7% and 96.4% of cases for
CT and MRI, respectively. Specificity and positive predictive
value (PPV) showed significant differences between the two
modalities (𝑝 = 0.048 versus 0.04), proving MRI to be more
reliable [4].
2.2. Scintigraphy and PET-CT. Thallium 201 (201Tl) scintig-
raphy is also useful in the evaluation of thymic lesions. It
represents cellularmetabolic activity, regional blood flow, and
the number of viable cells and is helpful in distinguishing
between normal thymus (NT), TH, and THA in cases of MG.
In cases of TH and THA a higher uptake was seen in different
periods compared to the ones seen in case of the NT [5]. The
disadvantages of this modality (high cost, low throughput,
and irradiation to the patient) precluded it from being widely
used in imaging of the thymus.
FDG-PET is more accurate in determining the metabolic
and functional features than the morphologic characteristics
of neoplasms with the possible recognition of residual or
recurrent disease. In the study of El-Bawab et al., the role of
FDG-PET was investigated among different thymic lesions
(TH, THA, and TC).The ranges of standardized uptake value
(SUV)were seen between 0.7–2.5 and 3.1–6.1 in TH andTHA,
respectively [6].
3. Thymoma
In cases where the diagnosis of THA is obvious and an abso-
lute indication for thymectomy is obtained, the most impor-
tant factor for the surgeon is the radio-clinicopathological
data concerning the THA.The following questions arise. (1) Is
the THA resectable, (2) does it infiltrate surrounding tissues
so that neoadjuvant therapy should come first, (3) what is the
rate of regression after neoadjuvant treatment, and (4) should
the resection be extended? These questions can be answered
after an extended and more meticulous imaging process with
the adaptation of the newly proposed TNM classification.
Relationship to surrounding tissues or organs (mainly great
vessels andmyocardium), the presence or lack of lymph node
metastases (N1, N2), and involvement of pleural/pericardial
sites should be investigated and mentioned.
3.1. Histological Classification, TNM, and Staging ofThymoma.
The diagnosis and classification of thymic epithelial tumors
(TET) have been a topic of argument for many years.
TETs have been uniformly classified by the WHO in 1999,
with emphasis on both clinical and functional aspects [7].
Type A tumors consist of rod-like epithelial cells without
the presence of atypia or neoplastic lymphocytes. Type
AB tumors resemble type A tumors but already represent
centers of neoplastic lymphocytes. Type B tumors feature
round-shaped epithelioid cells and are further divided into
subtypes (B1, B2, and B3). Type C defines thymic carcinoma
[8].
The recent uniform staging classification system was
processed by the Thymic Domain of the Staging and Prog-
nostic Factors Committee (TD-SPFC) in collaboration with
IASLC and ITMIG [9]. The most popular and widely used
Masaoka-Koga stage classification system (MK-SCS) [10]
was integrated into the new one; however some significant
modifications have also been introduced. These new changes
also have an important aspect in terms of imaging. One of
the most important changes is the elimination of a previously
essential focus, on which a tumor is encapsulated or, by
expanding beyond the border of the capsule, infiltrates the
thymus and neighbouring fat. This important modification
is based on the fact that all THAs are considered malignant,
irrelevant of the presence or lack of a capsule. In terms of
the TNM system, T1 has been divided into two subtypes,
namely, T1a (without mediastinal pleural involvement) and
T1b (involvement of the mediastinal pleura). In T2 cases
the pericardium is involved, while in T3, the lung, brachio-
cephalic vein, superior vena cava, chest wall, phrenic nerve,
and hilar pulmonary vessels are invaded. The aorta, great
branches of the pulmonary artery, myocardium, trachea, or
esophagus are involved in T4 tumors [9].
Preoperative imaging should point out the exact bor-
ders and presence or lack of invasion of THA concern-
ing the above-mentioned tissues or organs. In resectable
cases primary thymectomy is indicated, while in case of
an unresectable tumor, neoadjuvant treatment should be
applied.
An additional useful and important change is the veri-
fication of regional thymic lymph node levels. The N1 level
involves the anterior nodes, while the N2 level is limited
to the deep intrathoracic or cervical nodes [9, 11]. Lymph
node metastases most frequently occur in the anterior medi-
astinum and can be proved in 2% of THAs, 27% of TCs, and
28% of neuroendocrine thymic tumors (NETT) [11]. The M
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category has been defined as M0, the tumor being limited to
the primary mass, M1a with pericardial or pleural nodules
and M1b showing nodules inside the lung parenchyma or
being present in distant locations [9]. The N and M status of
THAs should be mentioned during imaging.
3.2. Imaging Features of Thymic Tumors. In the diagnostic
imaging of thymic epithelial tumors (TETs) and in the
differentiation between various WHO subtypes, CT imaging
plays a key role [12, 13]. In the study by Tomiyama et al., CT
characteristics of 53 primary thymic tumorswere investigated
retrospectively, according to the WHO classification. Type A
tumors were more frequently described by smooth contour
and a round shape, than TCs which more often appeared
with an irregular contour. Curvilinear calcifications were
seen in 20% of cases, usually meaning poor prognosis [14].
Mediastinal and hilar lymphadenopathy was found in nearly
half of TC cases [15]. According to the study conducted
by Sadohara et al. on distinguishing between subtypes of
THAs, they found that the likelihood of invasion seen on
CT was relatively low in low-risk THAs, intermediate in
high-risk THAs, and highest in TCs. Irregular contour,
necrotic or cystic component, heterogeneous enhancement,
lymphadenopathy, and great vessel invasion were help-
ful in differentiating low- or high-risk THAs from TCs
[16].
In the study conducted by Zhu et al. which focuses on
surgical outcomes, the rate of neoadjuvant treatment was 6%
in case of THAs (B2-B3-TC) with a 15% rate of incomplete
resection [17].The study by Hayes et al. described that in 87%
of incomplete resections, on preoperative CT peritumoral
fat was missed, compared to 66% rate in operable cases. In
cases of THAs where more than 50% circumference of the
adjacent vessel was involved, it was impossible to carry out
the resection [13]. The study by Korst et al. states that CT and
PET-CT are safe and useful methods in acquiring diagnosis
and deciding resectability after neoadjuvant chemoradiother-
apy. The rate of resection was 77% and the debulking rate
was only 5% after neoadjuvant therapy. With the help of this
method the rate of regression after neoadjuvant treatment
can be defined since the median SUV max decreased with
45% after neoadjuvant chemoradiotherapy [18]. Octreotide
scintigraphy is useful in the diagnosis of THA and its
metastases but it is not positive in TH [19, 20].
MRI can be helpful in differentiating among THA sub-
types and can predict the aggressivity of the disease. The
presence of a septum within the tumor is highly suggestive of
THA. OnMR imaging, the tumors showing smooth contour,
almost complete capsule, septum within the tumor, and
homogenous enhancement are more likely to be low-risk,
than high-risk THAs or TCs. Sadohara’s study states that
MRI is more accurate in detecting a capsule, septum, or a
haemorrhage than CT [16].
It has been declared that diffusion weighted imaging
(DWI) with the measurement of the apparent diffusion
coefficient (ADC) can be helpful to distinguish between
benign and malignant thymic lesions [21]. In addition, an
extremely useful aspect of thismodality is the ability to follow
the rate of regression in case of THAs after neoadjuvant
chemotherapy [21].
4. Role of Imaging in Myasthenia Gravis (MG)
The thymus is definitely involved in the pathogenesis of
MG. The incidence of thymic pathologies occurring among
MG patients is roughly 75% [22, 23]: with TH occurring in
60–77% and THA in 15–30% of cases [24]. In case of MG
thymectomy is necessary when the disease is accompanied
by THA; however when TH alone is present in MG patients,
thymectomy can be recommended, but it is not mandatory.
In the current clinical practice preoperative imaging of ETT
is not a routine procedure, although a number of MRI and
PET-CT reports state that in numerous cases ETT can be
detected on the neck or in the mediastinum. In terms of MG
thymectomies it would be extremely advantageous if some
information could be routinely obtained on imaging about
the localization of ETT.
Principles of surgical treatment of MG include complete
removal of the thymus with perithymic fat and possible ETT.
In MG cases usually two questions arise in terms of surgical
treatment. (1) Does the patient have THA? If the answer is
yes, it is an absolute indication for thymectomy. (2) Is there
any amount of ETT or “abnormal fat” around the thymus or
in themediastinum? In case ETT remains in themediastinum
or on the neck, the postoperative improvement of MG is
significantly worse.
4.1. Embryology of EctopicThymic Tissue. During its develop-
ment, thymic primordia arise from the third and fourth pha-
ryngeal pouches, become cylindrical, form the thymopha-
ryngeal ducts, and descend into the anterior mediastinum.
On the 8th gestational week, the thymic primordia fuse at
their lower poles and on the 14th to 16th weeks, the thymus
further differentiates into cortical andmedullary components
[25].
4.2. Prevalence and Imaging Techniques of Ectopic Thymic
Tissue. ETT may be found in various locations according to
the path of descent [25] and anywhere in the mediastinum,
mainly around the thymus. According to the study conducted
by Zielin´ski et al. [26] among 100 nonthymomatous patients
with MG, ectopic thymic foci were identified in 71% of
patients with the highest incidence in perithymic fat (37%)
and at the site of the aortopulmonary window (33%), in the
cervical region (10%), in the right and left pericardiophrenic
fat (7% each), and in the aortocaval groove (4%). Imaging
modalities of ETT include ultrasound (US) in infants, bearing
the advantages of short examination time, high resolution,
and the lack of ionizing radiation [27]. US features of ETT
include echogenic linear structures, which may refer to
connective tissue septa [28]. In terms of FDG-PET, a study by
El-Bawab et al. confirmed that FDG-PET was insufficient in
the detection of ETT [6].OnMRI, ETT appears homogenous,
isointense, or slightly hyperintense compared withmuscle on
T1 weighted images and hyperintense on T2 weighted images
[29].
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5. Surgical Point of View of Thymectomy
All THAs are considered malignant, due to their invasive and
metastatic potential, and thus should be surgically resected
in every case. In terms of surgical or nonsurgical treatment
planning, precise staging is one of themost important factors.
Preoperative imaging should mention T, N, and M status
of the THA with special attention to perithymic invasion.
Performing a complete resection of not only the gland itself
but also surrounding tissues containing thymic cells and
lymph nodes is of utmost importance. Incomplete resection
is associated with a high-recurrence rate and poor prognosis.
Throughout the years several surgical methods have been
described for the resection of THAs.The traditional approach
is the median sternotomy. The MIA (Minimally Invasive
Approach) for resection of THAs has gained widespread
popularity in recent years. These techniques include VATS
thymectomy from both sides, cervical thymectomy, subx-
iphoidal thymectomy, uniportal thymectomy, and robotic
resection. VATS thymectomy is a radical and expansively
used minimally invasive technique in the successful removal
of not only the gland but also surrounding thymic tissue
[30]. In advanced THA or TC cases extended resections are
recommended in combination with (neo) adjuvant chemo-/
radiotherapy [20].
6. Summary and Outlook
Imaging evaluation of the thymus comprises many obstacles,
mainly due to the fact that there are changes in size, shape,
consistency, and amount of fat with age to the organ. Precise
diagnosis and differentiation between each thymic condition
through imaging are essential for ideal surgical treatment
planning and avoiding overtreatment. While CT remains
the cornerstone of thymic imaging, MRI evolves as a useful
problem-solving modality for evaluation of various thymic
conditions and may remarkably support CT in everyday
clinical practice, especially in cases accompanied by MG in
combination with different types of the THAs or TC. CT
combined with PET imaging can be effectively used in the
diagnosis of advancedTHAs or TC,with control of regression
after neoadjuvant treatment, thus facilitating the rate of
surgical success. MRI is superior to CT in distinguishing
normal and hyperplastic thymus fromTHA.With the adding
of chemical shift sequence, MRI maintains a higher accuracy
in distinguishing THAs from TH which is essential in
the algorithm of treatment planning and deciding whether
surgery is needed. In terms of neoplastic conditions, MRI
proved to be an accurate modality in differentiating high-
and low-risk thymomas and can be helpful in separating
THA from TC. Distinguishing among various thymoma
subtypes on imaging is fundamental for further treatment
planning (preoperative chemo- and radiotherapy or primary
surgical resection) and achieving total remission. It would be
beneficial if the new proposed TNM and regional N-stage
classification for TETs could be more accurately described
by preoperative imaging similarly to the current N-stage
system for lung cancer, thus contributing to more precise
clinical classification. Treating patients with MG is one of the
mainstays of thymic surgery. Total removal of the thymus
and the resection of ETT in typical locations (perithymic fat,
aortopulmonary window, cervical region, right and left peri-
cardiophrenic fat, and aortocaval groove) are of paramount
importance in banishing MG. Preoperative imaging could be
extremely helpful in discovering possible ectopic thymic foci.
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